Bortezomib–Dexamethasone or Vincristine–Doxorubicin–Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients

Author： Chen RA   Tu Y   Cao Y   Liu L   Liang Y  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.39, Iss.5, 2011-09, pp. : 1975-1984

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma

By Jo Jae-Cheol   Kang Byung   Sym Sun   Lee Sung   Jang Geundoo   Kim Shin   Lee Dae   Kim Sang-We   Lee Jung   Suh Cheolwon  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 175-181

Springer Publishing Company

Access to resources Recommend Favorite

Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma

By Kortüüm Martin   Einsele Hermann  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1661-1663

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib continues to demonstrate superiority over high-dose dexamethasone in patients with relapsed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1621, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Thalidomide is effective when added to dexamethasone for the treatment of newly diagnosed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1527, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Bortezomib beats standard therapy in relapsed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite